title: Difference in growth hormone response to growth hormone-releasing hormone (GHRH) testing following GHRH subacute treatment in normal aging and growth hormone-deficient adults: possible perspectives for therapeutic use of GHRH or its analogs in elderly subjects?
abstract: The somatotroph axis function shows a decline in the elderly (somatopause). In particular growth hormone (GH) response to GH-releasing hormone (GHRH) is reduced in aged man but less than that observed in GH-deficient adults (GHDAs). Plasma GH response to GHRH (1 µg/kg BW) was significantly lower in four GHDAs than in seven healthy aged men 30, 60, and 90 min after acute GHRH administration. To verify whether a priming regimen might be able to increase the reduced GH response to GHRH, both healthy aged men and GHDA patients underwent repetitive administration of GHRH (100 µg GHRH intravenously as a single morning dose, every 2 days for 12 days). After the GHRH-priming regimen, plasma GH values 30, 60, and 90 min after the acute GHRH test were significantly higher than values at the corresponding time points before priming regimen in healthy aged men but not in GHDA patients. These findings confirmed that somatotroph cells become less sensitive to GHRH with normal aging and demonstrate that repetitive administration of GHRH restores the attenuated response only in healthy aged men but not in GHDA patients. This could support the possible use of GHRH or its analogs instead of recombinant human GH in elderly patients with the advantage of preserving the endogenous pulses of GH with the secretion of the different isoforms of GH. However, concerns arise about the possible role of these molecules in tumorigenesis and tumor growth promotion.
authors.affiliation: Endocrinology, General Hospital of Eboli, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Iovino
authors.forename: V
authors.initials: V
authors.lastname: Triggiani
authors.forename: V A
authors.initials: VA
authors.lastname: Giagulli
authors.forename: N
authors.initials: N
authors.lastname: Iovine
authors.forename: B
authors.initials: B
authors.lastname: Licchelli
authors.forename: F
authors.initials: F
authors.lastname: Resta
authors.forename: C
authors.initials: C
authors.lastname: Sabbà
authors.forename: E
authors.initials: E
authors.lastname: Tafaro
authors.forename: A
authors.initials: A
authors.lastname: Solimando
authors.forename: A
authors.initials: A
authors.lastname: Tommasicchio
authors.forename: E
authors.initials: E
authors.lastname: Guastamacchia
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000375:Aging / Q000097:blood* / Q000187:drug effects; D015415:Biomarkers / Q000097:blood; D004393:Dwarfism, Pituitary / Q000097:blood* / Q000188:drug therapy*; D013007:Growth Hormone-Releasing Hormone / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D019382:Human Growth Hormone / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D019382:Human Growth Hormone; D013007:Growth Hormone-Releasing Hormone